Special Issue "Hepatobiliary Malignancies: Recent Advancements and Future Directions"
Deadline for manuscript submissions: 30 June 2022.
Interests: liver surgery; liver tumor; liver fibrosis; biliary surgery; biliary disease; liver transplantation; pancreatic surgery; laparoscopic surgery
Hepatobiliary malignancies includes a variety of cancers such as hepatocellular carcinoma and cholangiocarcinoma and represent one of the most challenging human neoplasms to be treated. Compared to cancers of the gastrointestinal tracts, the development of therapeutic means is lagging behind due to the rarity of the diseases. The aggressive nature of the disease itself and the difficulty of early detection limit the number of patients eligible for curative treatment. In addition, surgery is often highly invasive and associated with high risk. Due to these complex factors, the therapeutic outcome of hepatobiliary malignancies is suboptimal, leaving much room for improvement.
There have been many highlights in recent years regarding the treatment of hepatobiliary malignancies. The development of molecular targeted agents and immunotherapies for hepatocellular carcinoma has revolutionized the treatment of advanced hepatocellular carcinoma. The introduction of minimally invasive laparoscopic surgery has increased the number of patients who benefit from surgery and may contribute to further expanding the indications for liver surgery. The indications for liver transplantation for hepatobiliary malignancies has gradually expanded and may be the last hope for patients who were otherwise incurable.
In the present Special Issue “Hepatobiliary Malignancies: Recent Advancements and Future Directions”, we would like to gather submissions that cover significant contributions in the following issues:
A. Surgical therapies
1) Resection: laparoscopic and robotic hepatobiliary surgeries, recent advancement and the future
2) Liver transplantation: expanding indications for hepatocellular carcinoma liver transplantation for hepatobiliary malignancies other than hepatocellular carcinoma (intrahepatic cholangiocarcinoma, perihilar cholangiocarcinoma, colorectal liver metastasis, and liver metastasis from endocrine tumors)
B. Pharmacological therapies
1) Molecular targeted therapies and immunotherapies for hepatocellular carcinoma
2) Pharmacological therapies for cholangiocarcinoma: recent advances and future directions
3) Genomic medicine for hepatobiliary malignancies
C. Non-surgical and non-pharmacological therapies for hepatobiliary malignancies
1) Ablation therapies for hepatocellular carcinoma
2) Transarterial therapies for hepatocellular carcinoma
3) Radiation therapies for hepatobiliary malignancies
Dr. Kojiro Taura
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Current Oncology is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- liver cancer
- hepatocellular carcinoma